MedPath

The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX- Stent Study)

Not Applicable
Withdrawn
Conditions
Cirrhosis of the Liver
Re-stenosis
Interventions
Device: BMS
Device: ZES
Registration Number
NCT02809248
Lead Sponsor
RWTH Aachen University
Brief Summary

The aim of the study is to choose an optimal stent and to get further knowledge about the mechanisms of the engraftment of a stent.

The occurrence of a hyperplasia of neointima can be minimized by application of a coated stent and a concurrent safety four weekly dual thrombocytes therapy

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • male and female patients with a severe dysfunction of liver
  • patient is planned a coronary stent implantation
  • adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel
  • written informed consent prior to study participation
Exclusion Criteria
  • younger than 18 years
  • pregnancy and breast-feeding
  • acute cardiac syndrome
  • contraindication against an intracardiac catheter
  • persons in dependence from the sponsor or working with the sponsor
  • participation in a parallel interventional clinical trial
  • patient has been committed to an institution by legal or regulatory order

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
uncoated stentBMSthe patient get a uncoated coronary stent implantation (BMS - bare metal stent)
coated stentZESthe patient get a coated coronary stent implantation (ZES - zotarolimus eluting stent)
Primary Outcome Measures
NameTimeMethod
the ideal stent (coated stent or uncoated stent)5 weeks
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath